Cellect Biotechnology, Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on September 17, 2021, by Cellect Biotechnology, Ltd. ("Cellect"), reports amendments to financing agreements with Quoin Pharmaceuticals, Inc. ("Quoin") and Altium Growth Fund, L.P. ("Altium"). The filing addresses the pending merger between Cellect and Quoin. The primary objective of the amendments is to reclassify certain warrants from liabilities to equity for accounting purposes, thereby improving the pro forma financial position of Cellect post-merger.
Key Financial Metrics and Pro Forma Impact
The filing provides a comparison of Cellect's pro forma financial information before and after the warrant amendments. The filing text does not provide current period revenue, operating profit, or cash flow data, as the company is in a pre-revenue or development stage focused on the merger transaction.
| Financial Metric | As Filed in Prospectus | After Amendments to Warrants |
|---|---|---|
| Total Assets | $36,921 | $36,921 |
| Total Liabilities | $44,778 | $22,948 |
| Total Shareholders' Equity (Deficiency) | $(7,857) | $13,973 |
| Total Liabilities and Shareholders' Equity | $36,921 | $36,921 |
Material Changes Versus Prior Period
The material change reported is the structural amendment of the Primary Financing Securities Purchase Agreement (SPA), Primary Financing Warrants, and Exchange Warrants. Key changes include:
- Fixed Share Counts: The number of shares issuable under Series A, B, and C Warrants and Exchange Warrants has been fixed (e.g., 4,276,252 for Series A and B) rather than determined by a formula.
- Exercise Price: The exercise price for all amended warrants is set at $3.98 per ADS.
- Removal of Reset Provisions: Provisions allowing for price resets based on trading prices at 45, 90, and 135 days have been deleted. This removal is critical for achieving equity classification.
- Reserve Limitations: The required reserve for warrant shares has been limited to the specific fixed amounts, removing previous multipliers (e.g., 400% of initial issued amount).
- Issuance Timing: The issuance date for Primary Financing Warrants is now set to 136 days following the closing of the Merger.
Guidance, Outlook, and Management Commentary
Management commentary focuses on the successful restructuring of the financing instruments to ensure equity treatment, which eliminates the pro forma deficit previously reported. The filing outlines the anticipated post-closing capitalization:
- Current Cellect stockholders will hold 980,934 ADSs.
- Cellect will issue 4,437,981 ADSs to existing stockholders and noteholders.
- 3,207,189 ADSs will be delivered to an Escrow Agent.
- Altium will receive Exchange Warrants for 1,238,429 ADSs.
- Upon exercise of the Series C Warrant, Altium will receive additional Series A and B Warrants for 2,389,670 ADSs each.
- The Dilution Escrow Shares are fixed at 1,826,975 ADSs, with 1,437,829 ADSs to be transferred to Cellect shareholders to ensure they retain at least 11.99% of fully diluted equity.
The filing notes that the Exchange Escrow Shares (previously 928,822) will be returned to Cellect for cancellation upon closing.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement and the closing date to confirm the 136-day issuance timeline for warrants.
- Confirm the impact of the September 10, 2021 ADR Ratio Adjustment on the fixed share counts and exercise prices.
- Review Exhibit 99.1 (Amendment Agreement) and Exhibit 99.2 (Letter Agreement) for the full legal text of the warrant modifications.
- Monitor the pro forma capitalization to ensure the 11.99% equity retention for pre-closing Cellect shareholders is maintained.
- Assess the liquidity implications of the reduced liability balance ($22,948 vs. $44,778) on the company's balance sheet post-merger.